scholarly journals Systematic Review With Meta-analysis: Prompt Endoscopy As the Initial Management Strategy for Uninvestigated Dyspepsia in Asi(Aliment Pharmacol Ther 2015;41:239-252)

2015 ◽  
Vol 21 (3) ◽  
pp. 443-444 ◽  
Author(s):  
Hye-Kyung Jung
2014 ◽  
Vol 41 (3) ◽  
pp. 239-252 ◽  
Author(s):  
S. L. Chen ◽  
K. A. Gwee ◽  
J. S. Lee ◽  
H. Miwa ◽  
H. Suzuki ◽  
...  

2018 ◽  
Vol 10 (8) ◽  
pp. 5
Author(s):  
Orreaga Zugasti Echarte

En este artículo se presenta una revisión sistemática y metaanálisis para determinar si la literatura indicaba que los videolaringoscopios suponen una ventaja sobre la laringoscopia directa cuando son utilizados por anestesiólogos experimentados en el manejo de la vía aérea difícil prevista. El éxito en la intubación al primer intento fue mayor en el grupo de los videolaringoscopios. Su uso también se asoció con una significativa mejor visión de la glotis y con un menor traumatismo de la mucosa de la vía aérea. Se concluye que la videolaringoscopia es un valor añadido para el anestesiólogo experimentado, mejorando la intubación en el primer intento, la visión de la glotis y reduciendo el trauma de la mucosa, pudiendo tener un papel importante en el abordaje inicial de la vía aérea difícil prevista. ABSTRACT This article presents a systematic review and meta-analysis to ascertain if the literature indicated if videolaryngoscopy conferred an advantage when used by experienced anaesthetists managing patients with a known difficult airway. First-attempt success of tracheal intubation was higher in the videolaryngoscopy group. Use of videolaryngoscopy was also associated with a significantly better view of the glottis and with a less rate of airway mucosal trauma. Videolaryngoscopy has added value for the experienced anaesthetist, improving first-time success, the view of the glottis and reducing mucosal trauma. It could become a standard of care in the initial management of the known difficult airway.


BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e029537 ◽  
Author(s):  
Derek Chew ◽  
Ranjani Somayaji ◽  
John Conly ◽  
Derek Exner ◽  
Elissa Rennert-May

ObjectivesInitial management of cardiac implantable electronic device (CIED) infection requires removal of the infected CIED system and treatment with systemic antibiotics. However, the optimal timing to device reimplantation is unknown. The aim of this study was to quantify the incidence of reinfection after initial management of CIED infection, and to assess the effect of timing to reimplantation on reinfection rates.DesignSystematic review and meta-analysis.InterventionsA systematic review and meta-analysis was performed of studies published up to February 2018. Inclusion criteria were: (a) documented CIED infection, (b) studies that reported the timing to device reimplantation and (c) studies that reported the proportion of participants with device reinfection. A meta-analysis of proportions using a random effects model was performed to estimate the pooled device reinfection rate.Primary and secondary outcome measuresThe primary outcome measure was the rate of CIED reinfection. The secondary outcome was all-cause mortality.ResultsOf the 280 screened studies, 8 met inclusion criteria with an average of 96 participants per study (range 15–220 participants). The pooled incidence rate of device reinfection was 0.45% (95% CI, 0.02% to 1.23%) per person year. A longer time to device reimplantation >72 hours was associated with a trend towards higher rates of reinfection (unadjusted incident rate ratio 4.8; 95% CI 0.9 to 24.3, p=0.06); however, the meta-regression analysis was unable to adjust for important clinical covariates. There did not appear to be a difference in reinfection rates when time to reimplantation was stratified at 1 week. Heterogeneity was moderate (I2=61%).ConclusionsThe incident rate of reinfection following initial management of CIED infection is not insignificant. Time to reimplantation may affect subsequent rates of device reinfection. Our findings are considered exploratory and significant heterogeneity limits interpretation.PROSERO registration numberCRD4201810960.


2020 ◽  
Vol 16 (4) ◽  
pp. 61-74 ◽  
Author(s):  
Paula Chu ◽  
Sarah Batson ◽  
Matthew Hodgson ◽  
Catherine R Mitchell ◽  
Anna Steenrod

Aim: To conduct a systematic review and meta-analysis feasibility of clinical, quality of life and economic evidence for neurotrophic tropomyosin-related receptor tyrosine kinases ( NTRK) inhibitors in patients with NTRK gene fusion-positive tumors. Materials & methods: Databases were searched for studies on NTRK inhibitors in adult and pediatric patients. Results: 27 publications reported clinical data for seven interventions. Efficacy/safety data were available for two interventions only. Four trials each reported data for larotrectinib and entrectinib with pooled analyses reporting objective response rates of 75% (95% CI: 61–85) and 57.4% (43.2–70.8), respectively. No publications reported economic or quality of life evidence. Conclusion: Preliminary data demonstrate that NTRK inhibitors are well tolerated and show impressive clinical benefit; corroboration of existing studies and real-world data are required.


PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0178802 ◽  
Author(s):  
Min Joung Kim ◽  
Incheol Park ◽  
Joon Min Park ◽  
Kyung Hwan Kim ◽  
Junseok Park ◽  
...  

BMJ ◽  
2019 ◽  
pp. l6483 ◽  
Author(s):  
Leonardo H Eusebi ◽  
Christopher J Black ◽  
Colin W Howden ◽  
Alexander C Ford

AbstractObjectiveTo determine the effectiveness of management strategies for uninvestigated dyspepsia.DesignSystematic review and network meta-analysis.Data sourcesMedline, Embase, Embase Classic, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov from inception to September 2019, with no language restrictions. Conference proceedings between 2001 and 2019.Eligibility criteria for selecting studiesRandomised controlled trials that assessed the effectiveness of management strategies for uninvestigated dyspepsia in adult participants (age ≥18 years). Strategies of interest were prompt endoscopy; test for Helicobacter pylori and perform endoscopy in participants who test positive; test for H pylori and eradication treatment in those who test positive (“test and treat”); empirical acid suppression; or symptom based management. Trials reported dichotomous assessment of symptom status at final follow-up (≥12 months).ResultsThe review identified 15 eligible randomised controlled trials that comprised 6162 adult participants. Data were pooled using a random effects model. Strategies were ranked according to P score, which is the mean extent of certainty that one management strategy is better than another, averaged over all competing strategies. “Test and treat” ranked first (relative risk of remaining symptomatic 0.89, 95% confidence interval 0.78 to 1.02, P score 0.79) and prompt endoscopy ranked second, but performed similarly (0.90, 0.80 to 1.02, P score 0.71). However, no strategy was significantly less effective than “test and treat.” Participants assigned to “test and treat” were significantly less likely to receive endoscopy (relative risk v prompt endoscopy 0.23, 95% confidence interval 0.17 to 0.31, P score 0.98) than all other strategies, except symptom based management (relative risk v symptom based management 0.60, 0.30 to 1.18). Dissatisfaction with management was significantly lower with prompt endoscopy (P score 0.95) than with “test and treat” (relative risk v “test and treat” 0.67, 0.46 to 0.98), and empirical acid suppression (relative risk v empirical acid suppression 0.58, 0.37 to 0.91). Upper gastrointestinal cancer rates were low in all trials. Results remained stable in sensitivity analyses, with minimal inconsistencies between direct and indirect results. Risk of bias of individual trials was high; blinding was not possible because of the pragmatic trial design.Conclusions“Test and treat” was ranked first, although it performed similarly to prompt endoscopy and was not superior to any of the other strategies. “Test and treat” led to fewer endoscopies than all other approaches, except symptom based management. However, participants showed a preference for prompt endoscopy as a management strategy for their symptoms.Systematic review registrationPROSPERO registration number CRD42019132528.


Sign in / Sign up

Export Citation Format

Share Document